Skip to content

BD Intelliport 516701Recalls & reported problems

Becton, Dickinson And Company · BASE · Class 2

Adverse event reports
1
Deaths reported
0
Injuries reported
0
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 50382905167015), received between Feb 3, 2021 and Feb 3, 2021 — classified as 1 malfunction.

The most frequently reported specific device problem is “Communication or Transmission Problem” (1 report).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. How this data works · Data updated Oct 13, 2026.

Most reported problems

Device problems

  • Communication or Transmission Problem1

Patient problems

  • No Clinical Signs, Symptoms or Conditions1
  • No Consequences Or Impact To Patient1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • MalfunctionFeb 3, 2021Communication or Transmission Problem; Communication or Transmission Problem

    IT WAS REPORTED THAT INTELLIPORT SYSTEM TABLET HAD SCREEN ISSUES AND REPORTED INCORRECT DOSING. THE FOLLOWING INFORMATION WAS PROVIDED BY THE INITIAL REPORTER: MATERIAL NO. 516701, BATCH NO. IT IS REPORTED CUSTOMER EXPERIENCED SCREEN ISSUES WITH TABLET. VERBIAGE RECEIVED, - USER CLAIMS TO HAVE ADMINISTERED 50 MCG OF FENTANYL BUT INTELLIPORT SYSTEM RECORDED 75 MCG. AN ENTER DOSE MESSAGE WAS NOT DISPLAYED AND HE WAS UNABLE TO EDIT THE INTELLIPORT RECORD. USER RECORDED 50MCG IN THE EPIC CHART.

    Patient problems: No Clinical Signs, Symptoms or Conditions; No Consequences Or Impact To Patient

    MAUDE report 11276946 ↗

Other Infusion safety management software devices

All Infusion safety management software devices →

Sources: FDA GUDID, MAUDE and Medical Device Recalls via openFDA. openFDA data is not validated for clinical or regulatory use.